Cytokinetics (CYTK) to Release Earnings on Tuesday

Cytokinetics (NASDAQ:CYTK) is projected to post its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect Cytokinetics to post earnings of ($1.48) per share and revenue of $8.0230 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:30 PM ET.

Cytokinetics Stock Up 0.2%

Shares of CYTK opened at $67.94 on Friday. Cytokinetics has a fifty-two week low of $29.31 and a fifty-two week high of $70.98. The company’s fifty day moving average is $63.86 and its two-hundred day moving average is $57.68. The firm has a market cap of $8.31 billion, a PE ratio of -10.80 and a beta of 0.54.

Insider Buying and Selling at Cytokinetics

In other Cytokinetics news, EVP Andrew Callos sold 52,486 shares of the business’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $65.95, for a total value of $3,461,451.70. Following the transaction, the executive vice president owned 50,660 shares in the company, valued at $3,341,027. The trade was a 50.89% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Wendell Wierenga sold 20,000 shares of the company’s stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $66.14, for a total transaction of $1,322,800.00. Following the completion of the transaction, the director directly owned 32,444 shares of the company’s stock, valued at approximately $2,145,846.16. The trade was a 38.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 151,385 shares of company stock valued at $9,817,158. 2.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Kemnay Advisory Services Inc. purchased a new position in Cytokinetics in the fourth quarter valued at about $27,000. Kestra Advisory Services LLC purchased a new position in shares of Cytokinetics during the 4th quarter valued at approximately $29,000. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Cytokinetics by 46.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 543 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 171 shares during the last quarter. Quarry LP acquired a new stake in shares of Cytokinetics during the third quarter worth approximately $30,000. Finally, Advisory Services Network LLC bought a new stake in shares of Cytokinetics in the third quarter worth $32,000.

Wall Street Analyst Weigh In

A number of research firms have issued reports on CYTK. Weiss Ratings reissued a “sell (d-)” rating on shares of Cytokinetics in a research report on Wednesday, January 21st. Needham & Company LLC increased their target price on shares of Cytokinetics from $72.00 to $84.00 and gave the stock a “buy” rating in a research report on Monday, December 22nd. B. Riley Financial raised their price target on shares of Cytokinetics from $90.00 to $108.00 and gave the company a “buy” rating in a report on Wednesday, January 21st. Citigroup reiterated a “market outperform” rating on shares of Cytokinetics in a research note on Monday, December 22nd. Finally, Citizens Jmp raised their target price on shares of Cytokinetics from $78.00 to $88.00 and gave the company a “market outperform” rating in a research note on Monday, December 22nd. Sixteen analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $88.28.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.